Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Up 1,984.9% in October

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPHGet Free Report) was the target of a significant increase in short interest in October. As of October 31st, there was short interest totalling 702,600 shares, an increase of 1,984.9% from the October 15th total of 33,700 shares. Based on an average daily volume of 1,540,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 34.8% of the company’s stock are sold short.

Shuttle Pharmaceuticals Trading Down 3.6 %

Shares of NASDAQ:SHPH traded down $0.04 during trading on Thursday, hitting $1.07. 103,182 shares of the company were exchanged, compared to its average volume of 470,504. The stock has a market capitalization of $3.16 million, a PE ratio of -0.32 and a beta of -1.32. Shuttle Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $4.95. The firm has a fifty day simple moving average of $1.37.

Shuttle Pharmaceuticals (NASDAQ:SHPHGet Free Report) last announced its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.96) earnings per share for the quarter.

Shuttle Pharmaceuticals Company Profile

(Get Free Report)

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .

See Also

Receive News & Ratings for Shuttle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shuttle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.